- document
-
Liu, J. (author), O'Brien, K.L. (author), Lynch, D.M. (author), Simmons, N.L. (author), La Porte, A. (author), Riggs, A.M. (author), Abbink, P. (author), Coffey, R.T. (author), Grandpre, L.E. (author), Seaman, M.S. (author), Landucci, G. (author), Forthal, D.N. (author), Montefiori, D.C. (author), Carville, A. (author), Mansfield, K.G. (author), Havenga, M.J. (author), Pau, M.G. (author), Goudsmit, J. (author), Barouch, D.H. (author), TNO Kwaliteit van Leven (author)A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans. Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus...article 2009
- document
-
Kuhlmann, K.F.D. (author), van Geer, M.A. (author), Bakker, C.T. (author), Dekker, J.E.M. (author), Havenga, M.J.E. (author), Oude Elferink, R.P.J. (author), Gouma, D.J. (author), Bosma, P.J. (author), Wesseling, J.G. (author), TNO Kwaliteit van Leven (author)Survival of patients with pancreatic cancer is poor. Adenoviral (Ad) gene therapy employing the commonly used serotype 5 reveals limited transduction efficiency due to the low amount of coxsackie-adenovirus receptor on pancreatic cancer cells. To identify fiber-chimeric adenoviruses with improved gene transfer, a library of Ad vectors based on...article 2009
- document
-
van Weel, V. (author), van Tongeren, R.B. (author), van Hinsbergh, V.W.M. (author), van Bockel, J.H. (author), Quax, P.H.A. (author), TNO Kwaliteit van Leven (author)Stimulation of vascular growth to treat limb ischemia is promising, and early results obtained from uncontrolled clinical trials using angiogenic agents, e.g., vascular endothelial growth factor, led to high expectations. However, negative results from recent placebo-controlled trials warrant further research. Here, current insights into...article 2008
- document
-
Pols, T.W.H. (author), Ottenhoff, R. (author), Vos, M. (author), Levels, J.H.M. (author), Quax, P.H.A. (author), Meijers, J.C.M. (author), Pannekoek, H. (author), Groen, A.K. (author), de Vries, C.J.M. (author), TNO Kwaliteit van Leven (author)NR4A nuclear receptors are induced in the liver upon fasting and regulate hepatic gluconeogenesis. Here, we studied the role of nuclear receptor Nur77 (NR4A1) in hepatic lipid metabolism. We generated mice expressing hepatic Nur77 using adenoviral vectors, and demonstrate that these mice exhibit a modulation of the plasma lipid profile and a...article 2008
- document
- Hu, L. (author), Bovenschen, N. (author), Havekes, L.M. (author), van Vlijmen, B.J.M. (author), Tamsma, J.T. (author), TNO Kwaliteit van Leven (author) article 2007
- document
-
Verhaagh, S. (author), de Jong, E. (author), Goudsmit, J. (author), Lecollinet, S. (author), Gillissen, G. (author), de Vries, M. (author), van Leuven, K. (author), Que, I. (author), Ouwehand, K. (author), Mintardjo, R. (author), Weverling, G.J. (author), Radošević, K. (author), Richardson, J. (author), Eloit, M. (author), Lowik, C. (author), Quax, P. (author), Havenga, M. (author), TNO Kwaliteit van Leven (author)Wild-type strains of mice do not express CD46, a high-affinity receptor for human group B adenoviruses including type 35. Therefore, studies performed to date in mice using replication-incompetent Ad35 (rAd35) vaccine carriers may underestimate potency or result in altered vector distribution. Here, it is reported that CD46 transgenic mice (MYII...article 2006
- document
-
TNO Kwaliteit van Leven (author), Lemckert, A.A.C. (author), Grimbergen, J. (author), Smits, S. (author), Hartkoorn, E. (author), Holterman, L. (author), Berkhout, B. (author), Barouch, D.H. (author), Vogels, R. (author), Quax, P. (author), Goudsmit, J. (author), Havenga, M.J.E. (author)Recombinant adenoviral vectors based on type 5 (rAd5) show great promise as a vaccine carrier. However, neutralizing activity against Ad5 is prevalent and high-titred among human populations, and significantly dampens Ad5-based vaccine modalities. The generation of alternative adenoviral vectors with low seroprevalence thus receives much...article 2006
- document
-
Krom, Y.D. (author), Gras, J.C.E. (author), Frants, R.R. (author), Havekes, L.M. (author), van Berkel, T.J. (author), Biessen, E.A.L. (author), van Dijk, K.W. (author), TNO Kwaliteit van Leven (author)Vascular smooth muscle (VSMC) and endothelial cells (EC) are particularly resistant to infection by type 5 adenovirus (Ad) vectors. To overcome this limitation and target Ad vectors to ubiquitously expressed α Vβ3/5 integrins, we have generated a linker protein consisting of the extracellular domain of the coxsackie adenovirus receptor (CAR)...article 2005
- document
-
van Weel, V. (author), Deckers, M.M.L. (author), Grimbergen, J.M. (author), van Leuven, K.J.M. (author), Lardenoye, J.W.H.P. (author), Schlingemann, R.O. (author), van Nieuw Amerongen, G.P. (author), van Bockel, J.H. (author), van Hinsbergh, V.W.M. (author), Quax, P.H.A. (author), Gaubius Instituut TNO (author)Therapeutic angiogenesis using vascular endothelial growth factor (VEGF) is considered a promising new therapy for patients with arterial obstructive disease. Clinical improvements observed consist of improved muscle function and regression of rest pain or angina. However, direct evidence for improved vascularization, as evaluated by angiography...article 2004
- document
-
Vogels, R. (author), Zuijdgeest, D. (author), van Rijnsoever, R. (author), Hartkoorn, E. (author), Damen, I. (author), de Béthune, M.-P. (author), Kostense, S. (author), Penders, G. (author), Helmus, N. (author), Koudstaal, W. (author), Cecchini, M. (author), Wetterwald, A. (author), Sprangers, M. (author), Lemckert, A. (author), Ophorst, O. (author), Koel, B. (author), van Meerendonk, M. (author), Quax, P. (author), Panitti, L. (author), Grimbergen, J. (author), Bout, A. (author), Goudsmit, J. (author), Havenga, M. (author)Replication-deficient human adenovirus type 5 (Ad5) can be produced to high titers in complementing cell lines, such as PER.C6, and is widely used as a vaccine and gene therapy vector. However, preexisting immunity against Ad5 hampers consistency of gene transfer, immunological responses, and vector-mediated toxicities. We report the...article 2003
- document
-
von der Thüsen, J.H. (author), van Vlijmen, B.J.M. (author), Hoeben, R.C. (author), Kockx, M.M. (author), Havekes, L.M. (author), van Berkel, T.J.C. (author), Biessen, E.A.L. (author)Background - The presence of the tumor-suppressor gene p53 in advanced atherosclerotic plaques and the sensitivity to p53-induced cell death of smooth muscle cells isolated from these plaques have fueled speculation about the role of p53 in lesion destabilization and plaque rupture. In this study, we describe a strategy to promote (thrombotic)...article 2002